Literature DB >> 18395488

Proteases and cystic fibrosis.

Judith A Voynow1, Bernard M Fischer, Shuo Zheng.   

Abstract

Cystic fibrosis is the most common, inherited fatal disease in Caucasians. The major cause of morbidity and mortality is chronic lung disease due to infection and inflammation in the airways leading to bronchiectasis and respiratory failure. The signature pathologic features of CF lung disease including abnormal mucus obstructing airways, chronic infection with Staphylococcus aureus, Pseudomonas aeruginosa and other gram negative bacteria, and a robust neutrophil-dominant airway inflammation, are exacerbated by unopposed proteases present at high concentrations in the ASL. There is strong evidence that proteases, particularly neutrophil elastase, contribute to the pathology of CF by impairing mucociliary clearance, interfering with innate immune functions, and perpetuating neutrophilic inflammation. The mechanisms employed by proteases to impact airway function in CF will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395488      PMCID: PMC2431113          DOI: 10.1016/j.biocel.2008.03.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  98 in total

1.  Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8.

Authors:  C Taggart; R J Coakley; P Greally; G Canny; S J O'Neill; N G McElvaney
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-01       Impact factor: 5.464

2.  Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines.

Authors:  Yoshiyuki Wada; Kazuhiro Yoshida; Yasuhiro Tsutani; Hideaki Shigematsu; Mamoru Oeda; Yuichi Sanada; Takahisa Suzuki; Hirozumi Mizuiri; Yoichi Hamai; Kazuaki Tanabe; Kei Ukon; Jun Hihara
Journal:  Oncol Rep       Date:  2007-01       Impact factor: 3.906

3.  alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.

Authors:  M Griese; P Latzin; M Kappler; K Weckerle; T Heinzlmaier; T Bernhardt; D Hartl
Journal:  Eur Respir J       Date:  2006-10-18       Impact factor: 16.671

4.  Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients.

Authors:  Amit Gaggar; Yao Li; Nathaniel Weathington; Margaret Winkler; Michele Kong; Patricia Jackson; J E Blalock; J P Clancy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-03-23       Impact factor: 5.464

5.  Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.

Authors:  H C Lai; S C FitzSimmons; D B Allen; M R Kosorok; B J Rosenstein; P W Campbell; P M Farrell
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

6.  Association between pulmonary function and sputum biomarkers in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Moira L Aitken; Frank J Accurso; Richard A Kronmal; Michael W Konstan; Jane L Burns; Scott D Sagel; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2007-01-18       Impact factor: 21.405

7.  Regulation of MUC5AC expression by NAD(P)H:quinone oxidoreductase 1.

Authors:  Shuo Zheng; Angela S Byrd; Bernard M Fischer; Amy R Grover; Andrew J Ghio; Judith A Voynow
Journal:  Free Radic Biol Med       Date:  2007-01-31       Impact factor: 7.376

8.  Neutrophil elastase inhibition of cell cycle progression in airway epithelial cells in vitro is mediated by p27kip1.

Authors:  Bernard M Fischer; Shuo Zheng; Rongrong Fan; Judith A Voynow
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-06-22       Impact factor: 5.464

9.  Airway remodelling in children with cystic fibrosis.

Authors:  Tom N Hilliard; Nicolas Regamey; Janis K Shute; Andrew G Nicholson; Eric W F W Alton; Andrew Bush; Jane C Davies
Journal:  Thorax       Date:  2007-05-25       Impact factor: 9.139

10.  Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease.

Authors:  Dominik Hartl; Philipp Latzin; Peter Hordijk; Veronica Marcos; Carsten Rudolph; Markus Woischnik; Susanne Krauss-Etschmann; Barbara Koller; Dietrich Reinhardt; Adelbert A Roscher; Dirk Roos; Matthias Griese
Journal:  Nat Med       Date:  2007-12-02       Impact factor: 53.440

View more
  66 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Proteases, cystic fibrosis and the epithelial sodium channel (ENaC).

Authors:  P H Thibodeau; M B Butterworth
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

3.  Effects of structure on inhibitory activity in a series of mechanism-based inhibitors of human neutrophil elastase.

Authors:  Dengfeng Dou; Guijia He; Rongze Kuang; Qingfong Fu; Radhika Venkataraman; William C Groutas
Journal:  Bioorg Med Chem       Date:  2010-08-05       Impact factor: 3.641

4.  Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.

Authors:  Sophia Karandashova; Apparao Kummarapurugu; Shuo Zheng; Le Kang; Shumei Sun; Bruce K Rubin; Judith A Voynow
Journal:  Pediatr Pulmonol       Date:  2018-04-06

5.  Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures.

Authors:  Carey A Hobbs; Maxime G Blanchard; Omar Alijevic; Chong Da Tan; Stephan Kellenberger; Sompop Bencharit; Rui Cao; Mehmet Kesimer; William G Walton; Ashley G Henderson; Matthew R Redinbo; M Jackson Stutts; Robert Tarran
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-11       Impact factor: 5.464

6.  Synthesis and analytical characterization of new thiazol-2-(3H)-ones as human neutrophil elastase (HNE) inhibitors.

Authors:  Letizia Crocetti; Gianluca Bartolucci; Agostino Cilibrizzi; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Marta Menicatti; Igor A Schepetkin; Andrei I Khlebnikov; Mark T Quinn; Claudia Vergelli
Journal:  Chem Cent J       Date:  2017-12-06       Impact factor: 4.215

7.  2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation.

Authors:  Kathryn L Griffin; Bernard M Fischer; Apparao B Kummarapurugu; Shuo Zheng; Thomas P Kennedy; Narayanam V Rao; W Michael Foster; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

8.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs.

Authors:  Megha Makam; Daisy Diaz; Julie Laval; Yael Gernez; Carol K Conrad; Colleen E Dunn; Zoe A Davies; Richard B Moss; Leonore A Herzenberg; Leonard A Herzenberg; Rabindra Tirouvanziam
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-17       Impact factor: 11.205

10.  Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.

Authors:  Apparao B Kummarapurugu; Daniel K Afosah; Nehru Viji Sankaranarayanan; Rahaman Navaz Gangji; Shuo Zheng; Thomas Kennedy; Bruce K Rubin; Judith A Voynow; Umesh R Desai
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.